Psoriasis drug launch marks Eli Lilly’s entry into dermatology domain

Drug firm Eli Lilly marches into India’s dermatological space with the launch of a timely innovation that will address the treatment of moderate-to-severe plaque psoriasis. The company has launched Copellor in the market after getting approval from the Drug Controller General of India (DCGI).

The drug is empowered to laser target a protein that has a key role in triggering and maintaining inflammation in psoriasis.

Copellor is a prescription medicine meant to be used only upon the advice of a professional dermatologist or rheumatologist and under medical supervision, the drug firm has stated. Psoriasis is a chronic auto-immune disorder of the skin in which prolonged inflammation leads to dry, thick, raised, red patches on the skin that continuously shed silvery scales.

Marking the development, Vineet Gupta, Managing Director, Eli Lilly and Company, India & India Subcontinent said, “Our foray into the dermatology segment strengthens Lilly's promise of bringing innovative medicines to India. Global Studies show that the impact psoriasis has on a patient's quality of life is comparable to that of 'serious' diseases such as cancer and heart failure,"

He further added that the new solution (Copellor, Ixekizumab) is expected to empower the healthcare provider fraternity with a fresh option for amplifying treatment outcomes for adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis, thereby addressing a huge unmet need in the country.

*This press release is published by VOH team.*